105 related articles for article (PubMed ID: 16385342)
1. ADAM22, expressed in normal brain but not in high-grade gliomas, inhibits cellular proliferation via the disintegrin domain.
D'Abaco GM; Ng K; Paradiso L; Godde NJ; Kaye A; Novak U
Neurosurgery; 2006 Jan; 58(1):179-86; discussion 179-86. PubMed ID: 16385342
[TBL] [Abstract][Full Text] [Related]
2. Cloning and chromosomal mapping of mouse ADAM11, ADAM22 and ADAM23.
Sagane K; Yamazaki K; Mizui Y; Tanaka I
Gene; 1999 Aug; 236(1):79-86. PubMed ID: 10433968
[TBL] [Abstract][Full Text] [Related]
3. LGI1 and LGI4 bind to ADAM22, ADAM23 and ADAM11.
Sagane K; Ishihama Y; Sugimoto H
Int J Biol Sci; 2008; 4(6):387-96. PubMed ID: 18974846
[TBL] [Abstract][Full Text] [Related]
4. Metalloproteinase-like, disintegrin-like, cysteine-rich proteins MDC2 and MDC3: novel human cellular disintegrins highly expressed in the brain.
Sagane K; Ohya Y; Hasegawa Y; Tanaka I
Biochem J; 1998 Aug; 334 ( Pt 1)(Pt 1):93-8. PubMed ID: 9693107
[TBL] [Abstract][Full Text] [Related]
5. Biological characterization of ADAM22 variants reveals the importance of a disintegrin domain sequence in cell surface expression.
Sagane K; Sugimoto H; Akaike A
J Recept Signal Transduct Res; 2010 Apr; 30(2):72-7. PubMed ID: 20156119
[TBL] [Abstract][Full Text] [Related]
6. Efficient ADAM22 surface expression is mediated by phosphorylation-dependent interaction with 14-3-3 protein family members.
Gödde NJ; D'Abaco GM; Paradiso L; Novak U
J Cell Sci; 2006 Aug; 119(Pt 16):3296-305. PubMed ID: 16868027
[TBL] [Abstract][Full Text] [Related]
7. A disintegrin and metalloproteinase 22 activates integrin β1 through its disintegrin domain to promote the progression of pituitary adenoma.
Xing B; Lei Z; Wang Z; Wang Q; Jiang Q; Zhang Z; Liu X; Qi Y; Li S; Guo X; Liu Y; Li X; Shu K; Zhang H; Bartsch JW; Nimsky C; Huang Y; Lei T
Neuro Oncol; 2024 Jan; 26(1):137-152. PubMed ID: 37555799
[TBL] [Abstract][Full Text] [Related]
8. Differential coding potential of ADAM22 mRNAs.
Gödde NJ; D'Abaco GM; Paradiso L; Novak U
Gene; 2007 Nov; 403(1-2):80-8. PubMed ID: 17884303
[TBL] [Abstract][Full Text] [Related]
9. ADAM 23/MDC3, a human disintegrin that promotes cell adhesion via interaction with the alphavbeta3 integrin through an RGD-independent mechanism.
Cal S; Freije JM; López JM; Takada Y; López-Otín C
Mol Biol Cell; 2000 Apr; 11(4):1457-69. PubMed ID: 10749942
[TBL] [Abstract][Full Text] [Related]
10. The LGI1-ADAM22 protein complex directs synapse maturation through regulation of PSD-95 function.
Lovero KL; Fukata Y; Granger AJ; Fukata M; Nicoll RA
Proc Natl Acad Sci U S A; 2015 Jul; 112(30):E4129-37. PubMed ID: 26178195
[TBL] [Abstract][Full Text] [Related]
11. Developmental regulation and neuronal expression of the cellular disintegrin ADAM11 gene in mouse nervous system.
Rybnikova E; Kärkkäinen I; Pelto-Huikko M; Huovila AP
Neuroscience; 2002; 112(4):921-34. PubMed ID: 12088751
[TBL] [Abstract][Full Text] [Related]
12. Structural characterization of the ectodomain of a disintegrin and metalloproteinase-22 (ADAM22), a neural adhesion receptor instead of metalloproteinase: insights on ADAM function.
Liu H; Shim AH; He X
J Biol Chem; 2009 Oct; 284(42):29077-86. PubMed ID: 19692335
[TBL] [Abstract][Full Text] [Related]
13. The disintegrin domain of ADAM9: a ligand for multiple beta1 renal integrins.
Mahimkar RM; Visaya O; Pollock AS; Lovett DH
Biochem J; 2005 Jan; 385(Pt 2):461-8. PubMed ID: 15361064
[TBL] [Abstract][Full Text] [Related]
14. Adam22 is a major neuronal receptor for Lgi4-mediated Schwann cell signaling.
Ozkaynak E; Abello G; Jaegle M; van Berge L; Hamer D; Kegel L; Driegen S; Sagane K; Bermingham JR; Meijer D
J Neurosci; 2010 Mar; 30(10):3857-64. PubMed ID: 20220021
[TBL] [Abstract][Full Text] [Related]
15. ADAM22 as a prognostic and therapeutic drug target in the treatment of endocrine-resistant breast cancer.
Bolger JC; Young LS
Vitam Horm; 2013; 93():307-21. PubMed ID: 23810013
[TBL] [Abstract][Full Text] [Related]
16. Metalloproteinase disintegrins ADAM8 and ADAM19 are highly regulated in human primary brain tumors and their expression levels and activities are associated with invasiveness.
Wildeboer D; Naus S; Amy Sang QX; Bartsch JW; Pagenstecher A
J Neuropathol Exp Neurol; 2006 May; 65(5):516-27. PubMed ID: 16772875
[TBL] [Abstract][Full Text] [Related]
17. LGI1-associated epilepsy through altered ADAM23-dependent neuronal morphology.
Owuor K; Harel NY; Englot DJ; Hisama F; Blumenfeld H; Strittmatter SM
Mol Cell Neurosci; 2009 Dec; 42(4):448-57. PubMed ID: 19796686
[TBL] [Abstract][Full Text] [Related]
18. Increased expression of disintegrin-metalloproteinases ADAM-15 and ADAM-9 following upregulation of integrins alpha5beta1 and alphavbeta3 in atherosclerosis.
Al-Fakhri N; Wilhelm J; Hahn M; Heidt M; Hehrlein FW; Endisch AM; Hupp T; Cherian SM; Bobryshev YV; Lord RS; Katz N
J Cell Biochem; 2003 Jul; 89(4):808-23. PubMed ID: 12858346
[TBL] [Abstract][Full Text] [Related]
19. Sequence-specific interaction between the disintegrin domain of mouse ADAM 3 and murine eggs: role of beta1 integrin-associated proteins CD9, CD81, and CD98.
Takahashi Y; Bigler D; Ito Y; White JM
Mol Biol Cell; 2001 Apr; 12(4):809-20. PubMed ID: 11294888
[TBL] [Abstract][Full Text] [Related]
20. Plexin-B1 indirectly affects glioma invasiveness and angiogenesis by regulating the RhoA/αvβ3 signaling pathway and SRPK1.
Chang Y; Li L; Zhang L; Guo X; Feng Z; Zhou J; Zhou S; Feng G; Han F; Huang W; Yang J; Huang F
Tumour Biol; 2016 Aug; 37(8):11225-36. PubMed ID: 26944058
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
